



January 9, 2026

**BSE Limited**

P J Towers,  
Dalal Street,  
Mumbai – 400 001

**Scrip Code: 543904****National Stock Exchange of India Limited**

Exchange Plaza, C-1, Block G,  
Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051

**Symbol: MANKIND**

Dear Sir/ Madam,

**Subject: Intimation of Board Meeting**

**Ref.: Regulation 29 & 50 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations")**

Pursuant to Regulation 29 & 50 of the Listing Regulations, we wish to inform you that a meeting of Board of Directors of the Company is scheduled to be held on Tuesday, February 3, 2026, inter-alia to consider and approve the unaudited standalone and consolidated financial results of the Company for the quarter and nine months ended on December 31, 2025.

Further, in continuation of our earlier intimation dated December 24, 2025 under subject 'Intimation of Closure of Trading Window under SEBI (Prohibition of Insider Trading) Regulations, 2015 and the Company's 'Code of Conduct for Prevention of Insider Trading', the trading window for trading in the securities of the Company shall remain closed till February 5, 2026.

The above notice is also being uploaded on the website of the Company at [www.mankindpharma.com](http://www.mankindpharma.com).

You are requested to kindly take the same on records.

Thanking You,

Yours Faithfully,

For Mankind Pharma Limited

**Hitesh Kumar Jain**  
**Company Secretary &**  
**Compliance Officer**

**MANKIND PHARMA LIMITED**

Regd. Office : 208, Okhla Ind. Estate, Phase - 3, New Delhi-110020 • Ph. : 011-46846700, 47476600  
CIN No. L74899DL1991 PLC044843 • E-mail : [contact@mankindpharma.com](mailto:contact@mankindpharma.com) • [www.mankindpharma.com](http://www.mankindpharma.com)